BerandaATHA • NASDAQ
add
Athira Pharma Inc
$0,30
Sebelum Jam Perdagangan Normal:(5,18%)-0,016
$0,29
Tutup: 3 Jul, 09.12.04 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,30
Rentang tahun
$0,22 - $3,67
Kapitalisasi pasar
11,76Â jt USD
Volume Rata-Rata
940,57Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 9,54Â jt | -65,56% |
Laba bersih | -9,14Â jt | 65,28% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -9,29Â jt | 66,14% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 36,67Â jt | -69,96% |
Total aset | 43,51Â jt | -67,40% |
Total liabilitas | 6,18Â jt | -76,86% |
Total ekuitas | 37,33 jt | — |
Saham yang beredar | 39,04 jt | — |
Harga terhadap nilai buku | 0,31 | — |
Tingkat pengembalian aset | -46,61% | — |
Tingkat pengembalian modal | -56,42% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -9,14Â jt | 65,28% |
Kas dari operasi | -14,66Â jt | 43,17% |
Kas dari investasi | -7,35Â jt | -156,37% |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | -22,02Â jt | -72,50% |
Arus kas bebas | -11,35Â jt | 32,75% |
Tentang
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
26
